In contrast, Gao et al. reported that miR-26a could inhibit the proliferation and migration of breast cancer cells through repression of MCL-1, and that miR-26a could increase the sensitivity of breast cancer cells to paclitaxel [38]. Here, MCL1 is linked to breast cancer.